Factors influencing survival in metastatic castration-resistant prostate cancer therapy

被引：4

作者：

Marchioni, Michele ^{[1
]}

Marandino, Laura ^{[2
]}

Amparore, Daniele ^{[3
]}

Berardinelli, Francesco ^{[1
]}

Mascitti, Marco ^{[1
]}

Ferro, Matteo ^{[4
]}

Campi, Riccardo ^{[5
]}

Schips, Luigi ^{[1
]}

机构：

[1] Univ G dAnnunzio, SS Annunziata Hosp, Dept Med Oral & Biotechnol Sci, Unit Urol, Chieti, Italy

[2] IRCCS San Raffaele Sci Inst, Urol Res Inst, Div Expt Oncol, Milan, Italy

[3] Univ Turin, San Luigi Gonzaga Hosp, Dept Urol, Turin, Italy

[4] IRCCS, Div Urol, European Inst Oncol, Milan, Italy

[5] Univ Florence, Careggi Hosp, Unit Urol Robot Surg & Renal Transplantat, Florence, Italy

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2022年 / 22卷 / 10期

关键词：

Metastatic prostate cancer; castration-resistant tumors; lutetium; enzalutamide; abiraterone acetate; taxanes; PARP inhibitors; olaparib; MITOXANTRONE PLUS PREDNISONE; CHEMOTHERAPY-NAIVE PATIENTS; ABIRATERONE ACETATE; DOUBLE-BLIND; ELDERLY-PATIENTS; OPEN-LABEL; MEN; ENZALUTAMIDE; DOCETAXEL; CABAZITAXEL;

D O I：

10.1080/14737140.2022.2114458

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Introduction The number of patients with metastatic castration-resistant prostate cancer (mCRPC) is expected to increase due to the long life expectancy of those with advanced disease who are also more commonly diagnosed today because of stage migration. Several compounds are available for treating these patients. Areas covered We reviewed currently available treatments for mCRPC, their mechanism of action and resistance, and we explored possible predictors of treatment success useful to predict survival in mCRPC patients. Expert opinion A combination of molecular, clinical, pathological, and imaging features is necessary to correctly estimate patients' risk of death. The combination of these biomarkers may allow clinicians to tailor treatments based on cancer history and patients' features. The search of predictive biomarkers remains an unmet medical need for most patients with mCRPC.

引用

页码：1061 / 1079

页数：19

共 97 条

[1] Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration [J].

Abida, Wassim ;

Patnaik, Akash ;

Campbell, David ;

Shapiro, Jeremy ;

Bryce, Alan H. ;

McDermott, Ray ;

Sautois, Brieuc ;

Vogelzang, Nicholas J. ;

Bambury, Richard M. ;

Voog, Eric ;

Zhang, Jingsong ;

Piulats, Josep M. ;

Ryan, Charles J. ;

Merseburger, Axel S. ;

Daugaard, Gedske ;

Heidenreich, Axel ;

Fizazi, Karim ;

Higano, Celestia S. ;

Krieger, Laurence E. ;

Sternberg, Cora N. ;

Watkins, Simon P. ;

Despain, Darrin ;

Simmons, Andrew D. ;

Loehr, Andrea ;

Dowson, Melanie ;

Golsorkhi, Tony ;

Chowdhury, Simon .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) :3763-+

[2] Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor [J].

Adelaiye-Ogala, Remi ;

Gryder, Berkley E. ;

Yen Thi Minh Nguyen ;

Alilin, Aian Neil ;

Grayson, Adlai R. ;

Bajwa, Wardah ;

Jansson, Keith H. ;

Beshiri, Michael L. ;

Agarwal, Supreet ;

Rodriguez-Nieves, Jose Antonio ;

Capaldo, Brian ;

Kelly, Kathleen ;

VanderWeele, David J. .

MOLECULAR CANCER THERAPEUTICS, 2020, 19 (07) :1436-1447

[3] Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects [J].

Aldea, Mihaela ;

Lam, Laurent ;

Orillard, Emeline ;

Llacer Perez, Casilda ;

Saint-Ghislain, Mathilde ;

Gravis, Gwenaelle ;

Flechon, Aude ;

Roubaud, Guilhem ;

Barthelemy, Philippe ;

Ricci, Francesco ;

Priou, Frank ;

Neviere, Zoe ;

Beaufils, Mathilde ;

Laguerre, Brigitte ;

Hardy, Anne-Claire ;

Helissey, Carole ;

Ratta, Raffaele ;

Borchiellini, Delphine ;

Pobel, Cedric ;

Joly, Florence ;

Castro, Elena ;

Thiery-Vuillemin, Antoine ;

Baciarello, Giulia ;

Fizazi, Karim .

EUROPEAN JOURNAL OF CANCER, 2021, 159 :87-97

[4] Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Luber, Brandon ;

Wang, Hao ;

Chen, Yan ;

Nakazawa, Mary ;

Nadal, Rosa ;

Paller, Channing J. ;

Denmeade, Samuel R. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

JAMA ONCOLOGY, 2015, 1 (05) :582-591

[5] AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer [J].

Antonarakis, Emmanuel S. ;

Lu, Changxue ;

Wang, Hao ;

Luber, Brandon ;

Nakazawa, Mary ;

Roeser, Jeffrey C. ;

Chen, Yan ;

Mohammad, Tabrez A. ;

Chen, Yidong ;

Fedor, Helen L. ;

Lotan, Tamara L. ;

Zheng, Qizhi ;

De Marzo, Angelo M. ;

Isaacs, John T. ;

Isaacs, William B. ;

Nadal, Rosa ;

Paller, Channing J. ;

Denmeade, Samuel R. ;

Carducci, Michael A. ;

Eisenberger, Mario A. ;

Luo, Jun .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11) :1028-1038

[6] Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers [J].

Aparicio, Ana M. ;

Shen, Li ;

Tapia, Elsa Li Ning ;

Lu, Jing-Fang ;

Chen, Hsiang-Chun ;

Zhang, Jiexin ;

Wu, Guanglin ;

Wang, Xuemei ;

Troncoso, Patricia ;

Corn, Paul ;

Thompson, Timothy C. ;

Broom, Bradley ;

Baggerly, Keith ;

Maity, Sankar N. ;

Logothetis, Christopher J. .

CLINICAL CANCER RESEARCH, 2016, 22 (06) :1520-1530

[7] Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial [J].

Armstrong, Andrew J. ;

Lin, Ping ;

Tombal, Bertrand ;

Saad, Fred ;

Higano, Celestia S. ;

Joshua, Anthony M. ;

Parli, Teresa ;

Rosbrook, Brad ;

van Os, Steve ;

Beer, Tomasz M. .

EUROPEAN UROLOGY, 2020, 78 (03) :347-357

[8] Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study [J].

Armstrong, Andrew J. ;

Halabi, Susan ;

Luo, Jun ;

Nanus, David M. ;

Giannakakou, Paraskevi ;

Szmulewitz, Russell Z. ;

Danila, Daniel C. ;

Healy, Patrick ;

Anand, Monika ;

Rothwell, Colin J. ;

Rasmussen, Julia ;

Thornburg, Blair ;

Berry, William R. ;

Wilder, Rhonda S. ;

Lu, Changxue ;

Chen, Yan ;

Silberstein, John L. ;

Kemeny, Gabor ;

Galletti, Giuseppe ;

Somarelli, Jason A. ;

Gupta, Santosh ;

Gregory, Simon G. ;

Scher, Howard I. ;

Dittamore, Ryan ;

Tagawa, Scott T. ;

Antonarakis, Emmanuel S. ;

George, Daniel J. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (13) :1120-+

[9] Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer [J].

Armstrong, Andrew J. ;

Garrett-Mayer, Elizabeth ;

de Wit, Ronald ;

Tannock, Ian ;

Eisenberger, Mario .

CLINICAL CANCER RESEARCH, 2010, 16 (01) :203-211

[10] Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial [J].

Bahl, A. ;

Oudard, S. ;

Tombal, B. ;

Ozguroglu, M. ;

Hansen, S. ;

Kocak, I. ;

Gravis, G. ;

Devin, J. ;

Shen, L. ;

de Bono, J. S. ;

Sartor, A. O. .

ANNALS OF ONCOLOGY, 2013, 24 (09) :2402-2408

← 1 2 3 4 5 6 7 8 9 10 →